Effects of angiotensin converting enzyme inhibitors on liver fibrosis in HIV and hepatitis c coinfection

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Reese, Lindsey J ^a   Tider, Diane S ^b,c   Stivala, Alicia C ^b,c   Fishbein, Dawn A ^d  

^a Infectious Disease of Indiana   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873800934     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/978790     Document Type: Article

References (61)

1. Rosenthal E., Poirée M., Pradier C., Perronne C., Salmon-Ceron D., Geffray L., Myers R. P., Morlat P., Pialoux G., Pol S., Cacoub P., Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003 17 12 1803 1809 2-s2.0-0042232018 10.1097/00002030-200308150-00009 (Pubitemid 37000098)
2. CDC, 2002, http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ 2002supp-vol8no1/figure2.htm
3. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., Snydman D. R., Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases 2001 32 3 492 497 2-s2.0-0035112776 10.1086/318501 (Pubitemid 32173638)
4. Weber R., Sabin C. A., Friis-Moller N., Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Archives of Internal Medicine 2006 166 15 1632 1641 (Pubitemid 44232373)
5. Pineda J. A., García-García J. A., Aguilar-Guisado M., Ríos-Villegas M. J., Ruiz-Morales J., Rivero A., Del Valle J., Luque R., Rodríguez-Baño J., González-Serrano M., Camacho A., Macías J., Grilo I., Gómez-Mateos J. M., Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007 46 3 622 630 2-s2.0-34548709023 10.1002/hep.21757 (Pubitemid 47436106)
6. Petrovic L. M., HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article. Liver International 2007 27 5 598 606 2-s2.0-34547115207 10.1111/j.1478-3231. 2007.01478.x (Pubitemid 47097308)
7. Jones R., Dunning J., Nelson M., HIV and hepatitis C co-infection. International Journal of Clinical Practice 2005 59 9 1082 1087
8. Sherman K. E., Rouster S. D., Chung R. T., Rajicic N., Hepatitis C virus prevalence among patients infected with human immunodefidency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clinical Infectious Diseases 2002 34 6 831 837 2-s2.0-0037087144 10.1086/339042 (Pubitemid 34194855)
9. Bräu N., Bini E. J., Shahidi A., Aytaman A., Xiao P., Stancic S., Eng R., Brown S. T., Paronetto F., Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. American Journal of Gastroenterology 2002 97 8 2071 2078 2-s2.0-0036678772 10.1016/S0002-9270(02)04281-8
10. Soto B., Sánchez-Quijano A., Rodrigo L., Olmo J. A. D., García-Bengoechea M., Hernández-Quero J., Rey C., Abad M. A., Rodríguez M., Sales Gilabert M., González F., Mirón P., Caruz A., Relimpio F., Torronteras R., Leal M., Lissen E., Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology 1997 26 1 1 5 2-s2.0-0342601406 10.1016/S0168-8278(97)80001-3 (Pubitemid 27072597)
11. Santos S. A., Kontorinis N., Dieterich D. T., Management of chronic hepatitis C virus in patients with HIV. Current Treatment Options in Gastroenterology 2005 8 6 433 441 2-s2.0-30344448552 10.1007/s11938-005-0029-5 (Pubitemid 43056139)
12. Soriano V., Martin-Carbonero L., Maida I., Garcia-Samaniego J., Nuñez M., New paradigms in the management of HIV and hepatitis C virus coinfection. Current Opinion in Infectious Diseases 2005 18 6 550 560 2-s2.0-27744498373 (Pubitemid 41634770)
13. Thein H. H., Yi Q., Dore G. J., Krahn M. D., Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008 22 15 1979 1991 2-s2.0-53549115066 10.1097/QAD.0b013e32830e6d51
14. Di Martino V., Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M., Matheron S., Le Moing V., Vachon F., Degott C., Valla D., Marcellin P., The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001 34 6 1193 1199 2-s2.0-0035179821 10.1053/jhep.2001.29201 (Pubitemid 33096592)
15. Graham C. S., Baden L. R., Yu E., Mrus J. M., Carnie J., Heeren T., Koziel M. J., Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clinical Infectious Diseases 2001 33 4 562 569 2-s2.0-0035882187 10.1086/321909 (Pubitemid 32709592)
16. Bataller R., Brenner D. A., Liver fibrosis. Journal of Clinical Investigation 2005 115 2 209 218 2-s2.0-14944385607 10.1172/JCI200524282 (Pubitemid 40385459)
17. Rockey D. C., Antifibrotic therapy in chronic liver disease. Clinical Gastroenterology and Hepatology 2005 3 2 95 107 2-s2.0-13544268721 10.1016/S1542-3565(04)00445-8 (Pubitemid 40220303)
18. George J., Roulot D., Koteliansky V. E., Bissell D. M., In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: a potential new therapy for hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 1999 96 22 12719 12724 2-s2.0-0033607304 10.1073/pnas.96.22.12719 (Pubitemid 29513569)
19. Hellerbrand C., Stefanovic B., Giordano F., Burchardt E. R., Brenner D. A., The role of TGF β 1 in initiating hepatic stellate cell activation in vivo. Journal of Hepatology 1999 30 1 77 87 2-s2.0-0032586690 10.1016/S0168-8278(99)80010-5 (Pubitemid 29023655)
20. Powell E. E., Edwards-Smith C. J., Hay J. L., Clouston A. D., Crawford D. H., Shorthouse C., Purdie D. M., Jonsson J. R., Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000 31 4 828 833 2-s2.0-0034024356 (Pubitemid 30169926)
21. Vlachogiannakos J., Tang A. K. W., Patch D., Burroughs A. K., Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001 49 2 303 308 2-s2.0-0034922565 10.1136/gut.49.2.303 (Pubitemid 32675127)
22. Bataller R., Ginès P., Nicolás J. M., Görbig M. N., GarciaRamallo E., Gasull X., Bosch J., Arroyo V., Rodés J., Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000 118 6 1149 1156 2-s2.0-0034120267 (Pubitemid 30346992)
23. Warner F. J., Lubel J. S., McCaughan G. W., Angus P. W., Liver fibrosis: a balance of ACEs? Clinical Science 2007 113 3-4 109 118 2-s2.0-34547556897 10.1042/CS20070026 (Pubitemid 47237907)
24. Bataller R., Sancho-Bru P., Ginès P., Lora J. M., Al-Garawi A., Solé M., Colmenero J., Nicolás J. M., Jiménez W., Weich N., Gutiérrez-Ramos J. C., Arroyo V., Rodés J., Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003 125 1 117 125 2-s2.0-0037772442 10.1016/S0016-5085(03)00695-4 (Pubitemid 36799113)
25. Yoshiji H., Noguchi R., Ikenaka Y., Kitade M., Kaji K., Tsujimoto T., Uemura M., Fukui H., Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Current Medicinal Chemistry 2007 14 26 2749 2754 2-s2.0-36248937878 10.2174/092986707782360169 (Pubitemid 350130918)
26. Pereira R. M., dos Santos R. A. S., Teixeira M. M., Leite V. H. R., Costa L. P., da Costa Dias F. L., Barcelos L. S., Collares G. B., Simões e Silva A. C., The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). Journal of Hepatology 2007 46 4 674 681 2-s2.0-33947174603 10.1016/j.jhep.2006.10.018 (Pubitemid 46400144)
27. Bataller R., Gäbele E., Parsons C. J., Morris T., Yang L., Schoonhoven R., Brenner D. A., Rippe R. A., Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005 41 5 1046 1055 2-s2.0-17844403732 10.1002/hep.20665 (Pubitemid 40593912)
28. Xu W., Song S., Huang Y., Gong Z., Effects of perindopril and valsartan on expression of transforming growth factor- β -Smads in experimental hepatic fibrosis in rats. Journal of Gastroenterology and Hepatology 2006 21 8 1250 1256 2-s2.0-33745843718 10.1111/j.1440-1746.2006.04331.x (Pubitemid 44034336)
29. Li X., Meng Y., Yang X. S., Mi L. F., Cai S. X., ACEI attenuates the progression of CCI4-induced rat hepatic fibrogenesis by inhibiting TGF- β 1, PDGF-BB, NF- B and MMP-2,9. World Journal of Gastroenterology 2005 11 31 4807 4811 2-s2.0-24044494889 (Pubitemid 41223287)
30. Jonsson J. R., Clouston A. D., Ando Y., Kelemen L. I., Horn M. J., Adamson M. D., Purdie D. M., Powell E. E., Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001 121 1 148 155 2-s2.0-0034961836 (Pubitemid 32591525)
31. Yoshiji H., Kuriyama S., Fukui H., Blockade of renin-angiotensin system in antifibrotic therapy. Journal of Gastroenterology and Hepatology 2007 22 1, supplement S93 S95 2-s2.0-34249818814 10.1111/j.1440-1746.2006.04663.x (Pubitemid 46849000)
32. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Fukui H., Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001 34 4 I 745 750 2-s2.0-0034802566 10.1053/jhep.2001.28231 (Pubitemid 32927999)
33. Wei H., Li D., Lu H., Zhan Y., Wang Z., Huang X., Pan Q., Xu Q., Effects of angiotensin II receptor blockade on hepatic fibrosis in rats. Chinese Journal of Hepatology 2000 8 5 302 304 2-s2.0-0034305657
34. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., Takahashi M., Akisawa N., Iwasaki S., Oben J. A., Onishi S., Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007 45 6 1375 1381 2-s2.0-34250323865 10.1002/hep.21638 (Pubitemid 46918321)
35. Toblli J. E., Mũoz M. C., Cao G., Mella J., Pereyra L., Mastai R., ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese zucker rats. Obesity 2008 16 4 770 776 2-s2.0-41549156590 10.1038/oby.2007.114 (Pubitemid 351465631)
36. Iwata K., Sohda T., Irie M., Takeyama Y., Anan A., Shakado S., Sakisaka S., Angiotensin II type 1 receptor antagonist improves the prognosis in rats displaying liver cirrhosis induced by a choline-deficient diet. Journal of Gastrointestinal and Liver Diseases 2008 17 1 21 25 2-s2.0-42449098980 (Pubitemid 351568869)
37. Türkay C., Yönem O., Arici S., Koyuncu A., Kanbay M., Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. Digestive Diseases and Sciences 2008 53 3 789 793 2-s2.0-39849101882 10.1007/s10620-007-9941-y (Pubitemid 351317094)
38. Kagami S., Border W. A., Miller D. E., Noble N. A., Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor- β expression in rat glomerular mesangial cells. Journal of Clinical Investigation 1994 93 6 2431 2437 2-s2.0-0028362076 (Pubitemid 24177156)
39. Brenner B. M., Cooper M. E., De Zeeuw D., Keane W. F., Mitch W. E., Parving H. H., Remuzzi G., Snapinn S. M., Zhang Z., Shahinfar S., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001 345 12 861 869 2-s2.0-0035922441 10.1056/NEJMoa011161
40. Cohn J. N., Tognoni G., A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001 345 23 1667 1675 2-s2.0-0035818884 10.1056/NEJMoa010713 (Pubitemid 33126822)
41. Yokohama S., Tokusashi Y., Nakamura K., Tamaki Y., Okamoto S., Okada M., Aso K., Hasegawa T., Aoshima M., Miyokawa N., Haneda M., Yoneda M., Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World Journal of Gastroenterology 2006 12 2 322 326 2-s2.0-33644755928 (Pubitemid 43336936)
42. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., Hasegawa T., Tokusashi Y., Miyokawa N., Nakamura K., Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 5 1222 1225 2-s2.0-7044222556 10.1002/hep.20420 (Pubitemid 39425579)
43. Terui Y., Saito T., Watanabe H., Togashi H., Kawata S., Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002 36 4 1022 2-s2.0-18644369234 10.1053/jhep.2002. 32679
44. Rimola A., Londoño M. C., Guevara G., Bruguera M., Navasa M., Forns X., García-Retortillo M., García-Valdecasas J. C., Rodes J., Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004 78 5 686 691 2-s2.0-4544342831 10.1097/01.TP.0000128913.09774.CE (Pubitemid 39244729)
45. Corey K. E., Shah N., Misdraji J., Abu Dayyeh B. K., Zheng H., Bhan A. K., Chung R. T., The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver International 2009 29 5 748 753 2-s2.0-64749115204 10.1111/j.1478-3231.2009.01973.x
46. Ueki M., Koda M., Shimizu T., Mitsuta A., Yamamoto T., Murawaki Y., Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepato-Gastroenterology 2009 56 93 1100 1104 2-s2.0-70350511929
47. Wai C. T., Greenson J. K., Fontana R. J., Kalbfleisch J. D., Marrero J. A., Conjeevaram H. S., Lok A. S. F., A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 2 518 526 2-s2.0-0042265556 10.1053/jhep.2003.50346 (Pubitemid 36919874)
48. Sterling R. K., Lissen E., Clumeck N., Sola R., Correa M. C., Montaner J., Sulkowski M. S., Torriani F. J., Dieterich D. T., Thomas D. L., Messinger D., Nelson M., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43 6 1317 1325 2-s2.0-33745547388 10.1002/hep.21178 (Pubitemid 43980111)
49. Vallet-Pichard A., Mallet V., Pol S., FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology 2006 44 3 769 2-s2.0-33748938070 10.1002/hep.21334 (Pubitemid 44433734)
50. Forns X., Ampurdanès S., Llovet J. M., Aponte J., Quintó L., Martínez-Bauer E., Bruguera M., Sánchez-Tapias J. M., Rodés J., Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 4 986 992 2-s2.0-0036789328 10.1016/S0270-9139(02)00107-6
51. Iacobellis A., Mangia A., Leandro G., Clemente R., Festa V., Attino V., Ricciardi R., Giacobbe A., Facciorusso D., Andriulli A., External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. American Journal of Gastroenterology 2005 100 4 868 873 2-s2.0-20244377842 10.1111/j.1572-0241.2005.40881.x (Pubitemid 40592381)
52. Sulkowski M. S., Montes de Oca R., Moore R., Thomas D., Prediction of hepatic fibrosis in HIV/HCV-infected patients: comparison of FIB-4, APRI, and the Johns Hopkins Fibrosis Index (JHFI). Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections 2006
53. Bourliere M., Penaranda G., Renou C., Botta-Fridlund D., Tran A., Portal I., Lecomte L., Castellani P., Rosenthal-Allieri M. A., Gerolami R., Ouzan D., Deydier R., Degott C., Halfon P., Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. Journal of Viral Hepatitis 2006 13 10 659 670 2-s2.0-33748745101 10.1111/j.1365-2893.2006.00736.x (Pubitemid 44401194)
54. Al-Mohri H., Cooper C., Murphy T., Klein M. B., Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Medicine 2005 6 6 375 378 2-s2.0-28444478688 10.1111/j.1468-1293. 2005.00330.x (Pubitemid 41723304)
55. Scheuer P. J., Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology 1991 13 3 372 374 2-s2.0-0026072529
56. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSwen R. N. M., Phillips M. J., Portmann B. G., Poulsen H., Scheuer P. J., Schmid M., Thaler H., Histological grading and staging of chronic hepatitis. Journal of Hepatology 1995 22 6 696 699 2-s2.0-0029039362 10.1016/0168-8278(95)80226-6
57. Kim M. Y., Baik S. K., Park D. H., Jang Y. O., Suk K. T., Yea C. J., Lee I. Y., Kim J. W., Kim H. S., Kwon S. O., Cho M. Y., Ko S. B., Chang S. J., Um S. H., Han K. H., Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. Journal of Gastroenterology 2008 43 11 889 896 2-s2.0-56649106258 10.1007/s00535-008-2239-9
58. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R., Goodman Z. D., Koury K., Ling M. H., Albrecht J. K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 9286 958 965 2-s2.0-0035934568 10.1016/S0140-6736(01)06102-5 (Pubitemid 32913521)
59. Jeffers L. J., Cassidy W., Howell C. D., Hu S., Reddy K. R., Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology 2004 39 6 1702 1708 2-s2.0-2542590982 10.1002/hep.20212 (Pubitemid 38702672)
60. Abu Dayyeh B. K., Yang M., Dienstag J. L., Chung R. T., The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Digestive Diseases and Sciences 2011 56 2 564 568 2-s2.0-79952453566 10.1007/s10620-010-1507-8
61. Shiffman M. L., Di Bisceglie A. M., Lindsay K. L., Morishima C., Wright E. C., Everson G. T., Lok A. S., Morgan T. R., Bonkovsky H. L., Lee W. M., Dienstag J. L., Ghany M. G., Goodman Z. D., Everhart J. E., Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 4 1015 1023 2-s2.0-11144358311 10.1053/j.gastro.2004.01.014 (Pubitemid 38451173)